ImaginAB

ImaginAb Launches Phase II C-IT Neo Trial using CD8+ Cell Imaging to Investigate Neoadjuvant Immunotherapy

Los Angeles, USA and New York, USA, December 14, 2022 - ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETâ„¢) imaging agent and radiopharmaceutical therapy (RPT) products, in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated Phase II trial to explore...
ImaginAb, 423 Hindry Ave. Suite D, Inglewood, CA 90301

+1.310.645.1211